<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11161393</article-id><article-id pub-id-type="pmc">2363746</article-id><article-id pub-id-type="pii">6691601</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1601</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bissett</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>McLeod</surname><given-names>H L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sheedy</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Collier</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pithavala</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Paradiso</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pitsiladis</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cassidy</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK</aff><aff id="aff2"><label>2</label>Agouron Pharmaceuticals Inc, La Jolla, California, USA</aff><aff id="aff3"><label>3</label>The Cancer Research Campaign, London, UK</aff><pub-date pub-type="ppub"><month>02</month><year>2001</year></pub-date><volume>84</volume><issue>3</issue><fpage>308</fpage><lpage>312</lpage><history><date date-type="received"><day>19</day><month>05</month><year>2000</year></date><date date-type="rev-recd"><day>02</day><month>10</month><year>2000</year></date><date date-type="accepted"><day>27</day><month>10</month><year>2000</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The novel folate analogue AG2034, which was designed as an inhibitor of GARFT (glycinamide ribonucleotide formyltransferase), was evaluated in this phase I study under the auspices of The Cancer Research Campaign, UK. AG2034 blocks de novo purine synthesis through inhibition of GARFT. A total of 28 patients with histologically proven intractable cancers were enrolled. AG2034 was administered as a short intravenous infusion once every 3 weeks. 8 dose levels ranging from 1&#x02013;11 mg/m<sup>2</sup> were evaluated with patients receiving up to 6 cycles. Dose-limiting toxicities in the form of mucositis, diarrhoea and vomiting were observed at doses of 6 mg/m<sup>2</sup> and above. Significant levels of thrombocytopenia, neutropenia and anaemia were also recorded. Other sporadic toxicities included fatigue and myalgia. The MTD with this schedule of AG2034 was 5 mg/m<sup>2</sup>. Most side effects occurred more frequently with cumulative dosing. In keeping with this, pharmacokinetic analysis revealed evidence of drug accumulation. The AG2034 AUC<sub>0&#x02013;24</sub> increased by a median of 184&#x00025; (range 20&#x02013;389&#x00025;) from cycle 1 to 3 in all 10 patients examined. No objective antitumour responses were observed in the study. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>folate analogue</kwd><kwd>AG2034</kwd><kwd>GARFT inhibitor</kwd></kwd-group></article-meta></front></article>


